X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35056) 35056
Newspaper Article (363) 363
Newsletter (226) 226
Book Chapter (56) 56
Magazine Article (47) 47
Book / eBook (27) 27
Web Resource (14) 14
Government Document (13) 13
Dissertation (5) 5
Publication (4) 4
Book Review (2) 2
Conference Proceeding (2) 2
Reference (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32412) 32412
female (28860) 28860
oncology (16931) 16931
ovarian neoplasms - drug therapy (16729) 16729
ovarian cancer (13477) 13477
middle aged (10797) 10797
cancer (10489) 10489
ovarian neoplasms - pathology (9509) 9509
adult (9308) 9308
chemotherapy (8801) 8801
aged (8275) 8275
animals (6947) 6947
cell line, tumor (6438) 6438
antineoplastic combined chemotherapy protocols - therapeutic use (5444) 5444
ovarian-cancer (5004) 5004
obstetrics & gynecology (4711) 4711
mice (4445) 4445
carcinoma (4401) 4401
antineoplastic agents - therapeutic use (4294) 4294
tumors (4138) 4138
ovarian neoplasms - metabolism (4135) 4135
prognosis (4102) 4102
cisplatin (3991) 3991
apoptosis (3866) 3866
expression (3845) 3845
male (3844) 3844
research (3761) 3761
ovarian neoplasms - genetics (3760) 3760
care and treatment (3621) 3621
treatment outcome (3410) 3410
antineoplastic agents - pharmacology (3406) 3406
ovarian neoplasms - surgery (3294) 3294
neoplasm staging (3232) 3232
breast cancer (3062) 3062
paclitaxel (3058) 3058
breast-cancer (2897) 2897
health aspects (2843) 2843
metastasis (2797) 2797
analysis (2763) 2763
survival (2706) 2706
cisplatin - administration & dosage (2661) 2661
drug resistance, neoplasm (2563) 2563
cancer therapies (2536) 2536
pharmacology & pharmacy (2476) 2476
ovarian neoplasms - mortality (2451) 2451
aged, 80 and over (2393) 2393
gene expression (2363) 2363
proteins (2355) 2355
apoptosis - drug effects (2327) 2327
therapy (2309) 2309
neoplasms - drug therapy (2239) 2239
ovarian neoplasms - therapy (2230) 2230
breast neoplasms - drug therapy (2174) 2174
paclitaxel - administration & dosage (2114) 2114
mice, nude (2111) 2111
combined modality therapy (2106) 2106
hematology, oncology and palliative medicine (2060) 2060
retrospective studies (2060) 2060
tumor cells, cultured (2028) 2028
genetic aspects (1963) 1963
surgery (1907) 1907
antineoplastic agents - administration & dosage (1901) 1901
disease-free survival (1883) 1883
antineoplastic combined chemotherapy protocols - adverse effects (1870) 1870
drug resistance (1863) 1863
dose-response relationship, drug (1860) 1860
cell biology (1850) 1850
cell proliferation - drug effects (1827) 1827
carboplatin (1792) 1792
ovarian carcinoma (1764) 1764
biochemistry & molecular biology (1750) 1750
drug therapy (1749) 1749
carboplatin - administration & dosage (1743) 1743
cisplatin - pharmacology (1737) 1737
medicine & public health (1731) 1731
medicine (1655) 1655
gene expression regulation, neoplastic (1651) 1651
research article (1648) 1648
mutation (1633) 1633
survival rate (1626) 1626
risk factors (1604) 1604
obstetrics and gynecology (1597) 1597
xenograft model antitumor assays (1592) 1592
cells (1590) 1590
development and progression (1559) 1559
survival analysis (1559) 1559
drug administration schedule (1525) 1525
immunohistochemistry (1522) 1522
medical prognosis (1492) 1492
antineoplastic agents - adverse effects (1487) 1487
kinases (1456) 1456
carcinoma, ovarian epithelial (1454) 1454
time factors (1448) 1448
adolescent (1447) 1447
resistance (1442) 1442
signal transduction (1413) 1413
cisplatin - therapeutic use (1400) 1400
medicine, research & experimental (1378) 1378
oncology, experimental (1376) 1376
neoplasm recurrence, local - drug therapy (1356) 1356
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33877) 33877
Japanese (619) 619
German (504) 504
French (360) 360
Chinese (279) 279
Russian (254) 254
Polish (131) 131
Italian (119) 119
Czech (57) 57
Spanish (54) 54
Hungarian (41) 41
Dutch (32) 32
Bulgarian (24) 24
Portuguese (21) 21
Danish (18) 18
Ukrainian (17) 17
Hebrew (16) 16
Swedish (13) 13
Croatian (11) 11
Korean (11) 11
Norwegian (8) 8
Finnish (7) 7
Serbian (7) 7
Slovak (6) 6
Romanian (5) 5
Turkish (5) 5
Arabic (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
EMBO molecular medicine, ISSN 1757-4684, 2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet, there... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Mesenchyme | Colorectal carcinoma | Genomes | Breast cancer | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Paclitaxel | Breast | Software | Tumors
Journal Article
Nature cell biology, ISSN 1476-4679, 2018, Volume 20, Issue 8, pp. 954 - 965
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To... 
PATHWAY CHOICE | STRAND BREAK REPAIR | RESECTION | DAMAGE-RESPONSE | 53BP1 | CLASS-SWITCH RECOMBINATION | FANCONI-ANEMIA | DIFFERENTIAL EXPRESSION ANALYSIS | POLYMERASE-ZETA | TELOMERES | CELL BIOLOGY | Osteosarcoma - drug therapy | Mad2 Proteins - metabolism | Humans | Multiprotein Complexes | Ovarian Neoplasms - pathology | Bone Neoplasms - pathology | DNA Breaks, Double-Stranded | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Telomere-Binding Proteins - genetics | DNA End-Joining Repair | HEK293 Cells | Female | Bone Neoplasms - genetics | Ovarian Neoplasms - metabolism | Bone Neoplasms - drug therapy | BRCA1 Protein - deficiency | Telomere-Binding Proteins - metabolism | Ovarian Neoplasms - drug therapy | Osteosarcoma - metabolism | DNA-Binding Proteins | Tumor Suppressor p53-Binding Protein 1 - metabolism | Recombinational DNA Repair | Tumor Suppressor p53-Binding Protein 1 - genetics | Cisplatin - pharmacology | Breast Neoplasms - drug therapy | Proteins - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Proteins - metabolism | Breast Neoplasms - pathology | Mad2 Proteins - genetics | Cell Line, Tumor | Mice | Osteosarcoma - genetics | Cell Cycle Proteins | Osteosarcoma - pathology | Care and treatment | DNA | Cancer cells | Breast cancer | Genetic aspects | Research | Gene expression | Single-stranded DNA | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Inactivation | Proteins | Ribose | Null cells | Deoxyribonucleic acid--DNA | BRCA2 protein | CRISPR | Deactivation | BRCA1 protein | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Oligosaccharides | Double-strand break repair | Screens | Cisplatin | Inhibitors | Prostate | Viability | Tumors | Telomere-Binding Proteins / metabolism | Osteosarcoma / genetics | Telomere-Binding Proteins / genetics | BRCA1 Protein / genetics | Cellular Biology | Genetics | Proteins / genetics | Osteosarcoma / drug therapy | Ovarian Neoplasms / genetics | Mad2 Proteins / genetics | Proteins / metabolism | Breast Neoplasms / drug therapy | Breast Neoplasms / metabolism | Tumor Suppressor p53-Binding Protein 1 / genetics | BRCA1 Protein / deficiency | Ovarian Neoplasms / metabolism | Mad2 Proteins / metabolism | Breast Neoplasms / pathology | Bone Neoplasms / genetics | Ovarian Neoplasms / pathology | Bone Neoplasms / pathology | Life Sciences | Bone Neoplasms / drug therapy | Ovarian Neoplasms / drug therapy | Osteosarcoma / metabolism | Biochemistry, Molecular Biology | Breast Neoplasms / genetics | Drug Resistance, Neoplasm / genetics | Osteosarcoma / pathology | Bone Neoplasms / metabolism | Poly(ADP-ribose) Polymerase Inhibitors / pharmacology | Cisplatin / pharmacology | Molecular biology | Tumor Suppressor p53-Binding Protein 1 / metabolism | Cancer
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
PloS one, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145754
... clinical response to their primary therapy, nearly half will develop disease recurrence within 18 months and the majority will die from disease recurrence within 5 years... 
CA-125 | MULTIDISCIPLINARY SCIENCES | EPITHELIAL OVARIAN-CANCER | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Deoxyribonucleic acid | DNA
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 2019, Volume 84, Issue 3, pp. 487 - 499
.... While their function in hepatic metabolism of taxanes is well established, expression of these enzymes in solid tumors may play a role in the in situ metabolism of drugs as well, potentially... 
Intratumoral | Ritonavir | Paclitaxel | Docetaxel | CYP | Review | Journal Article | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | PREGNANE-X RECEPTOR | IMMUNOHISTOCHEMICAL LOCALIZATION | DOCETAXEL RESISTANCE | CYP3A4 EXPRESSION | TARGETED THERAPIES | MESSENGER-RNA | ONCOLOGY | P450-MEDIATED METABOLISM | BIOLOGICAL-ACTIVITY | PHARMACOLOGY & PHARMACY | HIV-1 PROTEASE INHIBITOR | METABOLIZING-ENZYMES | Lung Neoplasms - drug therapy | Taxoids - pharmacology | Humans | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Breast Neoplasms - enzymology | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Endometrial Neoplasms - enzymology | Lung Neoplasms - enzymology | Neoplasms - enzymology | Breast Neoplasms - drug therapy | Ovarian Neoplasms - enzymology | Neoplasms - drug therapy | Breast Neoplasms - pathology | Cytochrome P-450 CYP3A - metabolism | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasms - pathology | Antimitotic agents | Protease inhibitors | Proteases | Pharmacy | Cytochrome P-450 | Physiological aspects | Drugstores | Antineoplastic agents | Ovarian cancer | Cytochrome | Enzymes | Cytochrome P450 | Proteinase inhibitors | Taxane | Metabolism | Anticancer properties | Antitumor agents | Lungs | Drug metabolism | Breast | Solid tumors | Taxanes | Prostate | Endometrium | Tumors | Cytochromes P450
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 15, pp. 2512 - 2519
Journal Article
Nature (London), ISSN 1476-4687, 2013, Volume 497, Issue 7447, pp. 108 - 112
...). Repeat biopsies to study genomic evolution as a result of therapy are difficult, invasive and may be confounded by intra-tumour heterogeneity(3,4... 
HETEROGENEITY | LUNG-CANCER | ACTIVATION | EVOLUTION | VARIANTS | AXL | MULTIDISCIPLINARY SCIENCES | TAMOXIFEN RESISTANCE | TUMOR-CELLS | MUTATIONS | Lung Neoplasms - drug therapy | Genomics | Humans | ErbB Receptors - genetics | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Neoplasms - genetics | DNA Mutational Analysis | Female | Antineoplastic Agents - pharmacology | DNA, Neoplasm - analysis | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Intercellular Signaling Peptides and Proteins - genetics | Breast Neoplasms - drug therapy | Genome, Human - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Exome - genetics | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Retinoblastoma Protein - genetics | Plasma - chemistry | Alleles | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasms - pathology | Mediator Complex Subunit 1 - genetics | Drug Resistance, Neoplasm - drug effects | Evolution, Molecular | Antimitotic agents | Care and treatment | Physiological aspects | Dosage and administration | Genetic aspects | Research | Nucleotide sequencing | Drug resistance | Antineoplastic agents | DNA sequencing | Blood plasma | Cancer | Plasma | Biopsy | Breast cancer | Genomes | Mutation | Patients | Deoxyribonucleic acid--DNA | Tumors
Journal Article